Sickle-cell disease
Everyone wants the best for their children, but sometimes biological miscues obstruct that hope. This is true for sickle-cell disease, a disorder in which red blood cells take on an abnormal shape — leading to pain, organ damage and shorter lives.
This Nature Outlook is editorially independent, produced with financial support from a third party. About this content.
Nature is pleased to acknowledge financial support from CSL Behring in producing this Outlook. The sponsor retains sole responsibility for the following message.
CSL Behring is a global biotherapeutics leader driven by our promise to save lives. We meet patients’ needs using the latest technologies to develop and deliver innovative therapies.
Our commitment to remain at the forefront of innovation is stronger than ever. For patients living with sickle cell disease (SCD), we are conducting a clinical trial of plasma-derived Hemopexin (CSL889) for treatment of acute vaso-occlusive crisis.
The company offers the broadest range of products in the industry for treating coagulation disorders, primary immune deficiencies, hereditary angioedema, respiratory disease, and neurological disorders. CSL Behring’s products are also used in cardiac surgery, burn treatment and to prevent hemolytic disease of the newborn. The company operates one of the world’s largest plasma collection networks, CSL Plasma. The parent company, CSL Limited (ASX:CSL; USOTC:CSLLY), headquartered in Melbourne, Australia, employs more than 27,000 people, and delivers its life-saving therapies to people in more than 100 countries. For more information visit at CSLBehring.com/Vita and follow us on Twitter.com/CSLBehring.
